Drug profile · INN
venetoclax
VENCLEXTA
venetoclax (VENCLEXTA) is a apoptosis regulator bcl-2 inhibitor. Associated with AbbVie. Route of administration: oral. Current US regulatory status: approved.
Drug details — venetoclax
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 8
- Programs
- 87
- Data quality
- 0.84
Quick answer
venetoclax (VENCLEXTA) is a apoptosis regulator bcl-2 inhibitor. Associated with AbbVie. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Apoptosis regulator Bcl-2 inhibitor
Primary target: Apoptosis regulator Bcl-2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Lilly to Spotlight Growing Hematology Portfolio at 2026 EHA Annual Meeting: Key Data and Strategic Implications
Lilly will present positive Phase 3 BRUIN CLL-322 results at the 2026 EHA Annual Meeting, comparing pirtobrutinib plus venetoclax and rituximab against venetoclax and rituximab. The presentation underscores Lilly's expanding hematology portfolio, bolstered by recent acquisitions of Ajax Therapeutics and Kelonia Therapeutics.
Eli Lilly's Foundayo (Orforglipron) Receives FDA Approval for Obesity Treatment as Company Reports Strong Q1 2026 Results
Eli Lilly announces FDA approval of Foundayo (orforglipron) for obesity treatment alongside positive Phase 3 results and raised full-year guidance in Q1 2026.
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2025027051
INHIBITEURS DE SPHINGOSINE-1-PHOSPHATE LYASE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
granted -
WO 2024175803
COMPOSÉS POUR LE TRAITEMENT DE MALADIES MYÉLOÏDES AVEC DES ANOMALIES CHROMOSOMIQUES
granted -
WO 2024146923
INHIBITEURS DE POLYMÉRISATION DE TUBULINE
granted -
WO 2022234069
NOUVEAUX DÉRIVÉS DE 2-AMINOOXAZOLE ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES INFECTIEUSES
granted -
EP 3144307
NEUE OXAZOL DERIVATEN ALS SYK KINASEHEMMER
granted -
WO 2016085391
DÉRIVÉS DE BIS (SULFONAMIDE) ETLEUR UTILISATION COMME INHIBITEURS DE MPGES
granted -
WO 2016085392
DÉRIVÉS DE BIS (SULFONAMIDE) ET LEUR UTILISATION COMME INHIBITEURS DE MPGES
granted -
WO 2016071511
TRAITEMENT DU SYNDROME D'ACTIVATION MASTOCYTAIRE (SAMA) AVEC LE MASINITIB
granted
Frequently asked questions
What is venetoclax?
venetoclax (VENCLEXTA) is a apoptosis regulator bcl-2 inhibitor. Associated with AbbVie. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for venetoclax?
VENCLEXTA is a marketed brand name for venetoclax. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of venetoclax?
venetoclax has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.